BCYC News and Press, Bicycle Therapeutics plc From 03/10/20

- BT1718 on track for Phase IIa initiation in 2020; BT5528 Phase I dose escalation is ongoing; BT8009 on track for Phase I trial initiation in 2020 - IND-enabling activities for lead TICA™ BT7480 continue to progress - Cash was $92.1 million at December 31, 2019, which excl...

Gainers:  Spherix (NASDAQ: SPEX ) +146% . More news on: Spherix Incorporated, AIM ImmunoTech Inc., LightPath Technologies, Inc., Stocks on the move, , Read more ...

The severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2 for short, has definitely made its presence felt on Wall Street during the opening weeks of 2020. Despite a strong start to 2020, the  Dow Jones Industrial Average , the  Nasdaq Composite , and the  S&P 5...

Bicycle Therapeutics, PLC (NASDAQ: BCYC) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “Bicycle today announced a new strategic collaboration agreement with Genentech to discover, develop, and commercialize novel Bicycle-based ...

The market may have caught a cold this week, but that doesn't mean that there aren't a number of attractive buying opportunities. Personally, I'm always on the hunt for a good bargain. So I view this historically ugly pullback basically as nothing more than a chance to buy some of my favorite na...

Bicycle Therapeutics ( BCYC +2.9% ) trades higher after announcing a strategic collaboration with Roche's ( OTCQX:RHHBY ) Genentech to develop and commercialize Bicycle-based immuno-oncology therapies. More news on: Bicycle Therapeutics plc, Roche Holding Ltd ADR, Roche Holding Ltd, He...

Bicycle will receive a $30 million upfront payment; upfront payment and potential discovery, development, regulatory and commercial milestones could total up to $1.7 billion Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of ...

Picking home-run stocks -- or stocks capable of generating exponential returns on capital -- is no easy matter. That being said, there has arguably never been a more favorable environment for risk-tolerant investors on the hunt for unusual growth opportunities.  The fact of the matter is t...

* This article was originally published for ROTY subscribers on Jan. 24th, but has been updated where necessary. Despite the recent rebound, the story remains in early innings with substantial upside potential ahead should internal efforts in oncology and/or partnered projects continue to de...

Cancer Research UK to fund exploratory development of BT7401 through a Phase IIa clinical study Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) tech...